Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

“Our higher target reflects confidence in Dupilumab’s commercial COPD opportunity, adding to our already positive outlook for Regeneron on an ophthalmology franchise renewed by 8mg ...

A pivotal phase 3 trial of dupilumab (Dupixent ... The topline results were announced in a release by Sanofi and Regeneron, which said more complete results will be presented in an upcoming ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

The safety profile of dupilumab was consistent with that observed in previous clinical trials. Adverse events ... President and Chief Scientific Officer at Regeneron, and a principal inventor ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...

First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and ...